ARTICLE | Company News
FDA to discuss pulmonary product from GSK, Theravance
December 14, 2012 2:02 AM UTC
FDA's Pulmonary-Allergy Drugs Advisory Committee will meet on March 7, 2013, to discuss an NDA from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and partner Theravance Inc. (NASDAQ:THRX) for Breo fluticaso...